Eliciting a single amino acid change by vaccination generates antibody protection against group 1 and group 2 influenza A viruses

通过疫苗接种诱导单个氨基酸改变,即可产生针对第 1 组和第 2 组甲型流感病毒的抗体保护作用。

阅读:5
作者:Rashmi Ray ,Faez Amokrane Nait Mohamed ,Daniel P Maurer ,Jiachen Huang ,Berk A Alpay ,Larance Ronsard ,Zhenfei Xie ,Julianna Han ,Monica Fernandez-Quintero ,Quynh Anh Phan ,Rebecca L Ursin ,Mya Vu ,Kathrin H Kirsch ,Thavaleak Prum ,Victoria C Rosado ,Thalia Bracamonte-Moreno ,Vintus Okonkwo ,Julia Bals ,Caitlin McCarthy ,Usha Nair ,Masaru Kanekiyo ,Andrew B Ward ,Aaron G Schmidt ,Facundo D Batista ,Daniel Lingwood

Abstract

Broadly neutralizing antibodies (bnAbs) targeting the hemagglutinin (HA) stem of influenza A viruses (IAVs) tend to be effective against either group 1 or group 2 viral diversity. In rarer cases, intergroup protective bnAbs can be generated by human antibody paratopes that accommodate the conserved glycan differences between the group 1 and group 2 stems. We applied germline-engaging nanoparticle immunogens to elicit a class of cross-group bnAbs from physiological precursor frequency within a humanized mouse model. Cross-group protection depended on the presence of the human bnAb precursors within the B cell repertoire, and the vaccine-expanded antibodies enriched for an N55T substitution in the CDRH2 loop, a hallmark of the bnAb class. Structurally, this single mutation introduced a flexible fulcrum to accommodate glycosylation differences and could alone enable cross-group protection. Thus, broad IAV immunity can be expanded from the germline repertoire via minimal antigenic input and an exceptionally simple antibody development pathway.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。